SCHEMBL3604462

SCHEMBL3604462

CC(C)(C)OC(=O)C1CNCC2C(=O)N(c3ccc(F)c(F)c3)CN12

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.40
HDAC1 Q13547 5/20 0.37
HDAC8 Q9BY41 5/20 0.37
HDAC6 Q9UBN7 5/20 0.37
HDAC5 Q9UQL6 1/20 0.36
BPTF Q12830 1/20 0.36
ADAMTS5 Q9UNA0 5/20 0.35
MMP13 P45452 2/20 0.35
MMP14 P50281 2/20 0.35
MMP2 P08253 1/20 0.35
PRKCZ Q05513 1/20 0.34
ADAM17 P78536 1/20 0.34
NR1H2 P55055 1/20 0.33
NR1H3 Q13133 1/20 0.33
CASP3 P42574 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
CPB2 Q96IY4 1/20 0.32
CREBBP Q92793 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3608105 0.93 HDAC1 (0.34) TSHRHDAC1HDAC8HDAC6HDAC5
SCHEMBL3605596 0.88 ALDH1A1 (0.37) PRKCZMEN1KMT2A
SCHEMBL3609805 0.88 ALDH1A1 (0.35) MEN1KMT2A
SCHEMBL3608568 0.87 SLC6A2 (0.39) HDAC1HDAC8HDAC6ADAM17
SCHEMBL3606120 0.87 POLB (0.37) PRKCZ
SCHEMBL3607088 0.85 NPC1 (0.36) TSHRHDAC1HDAC8HDAC6NR1H2
SCHEMBL3604816 0.85 GPR119 (0.36) NR1H2NR1H3CASP3
SCHEMBL3601055 0.85 GPR119 (0.41) TSHRNR1H2NR1H3KMT2A
SCHEMBL3606731 0.85 OPRM1 (0.38) PRKCZNR1H2NR1H3CASP3MEN1
SCHEMBL3597127 0.85 DDB1 (0.34) NR1H2NR1H3CASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100004249-A1 Bicyclic heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-01-07 US disclosed
EP-2039695-A1 BICYCLIC HETEROCYCLIC COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2009-03-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004249-A1 Bicyclic heterocyclic compound and use thereof HTR2C, HTR5A, HTR2A TSHR 383/4885HDAC1 351/4885HDAC8 271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.